JGC
TRVI icon

J. Goldman & Co’s Trevi Therapeutics TRVI Stock Holding History

J. Goldman & Co’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.83M Sell
236,959
-207,398
-47% -$2.32M 0.08% 266
2025
Q4 		$5.56M Sell
444,357
-348,449
-44% -$4.03M 0.15% 178
2025
Q3 		$7.25M Sell
792,806
-186,292
-19% -$1.4M 0.18% 150
2025
Q2 		$5.36M Buy
979,098
+777,991
+387% +$4.84M 0.13% 193
2025
Q1 		$1.26M Sell
201,107
-336,502
-63% -$1.61M 0.03% 344
2024
Q4 		$2.21M Buy
537,609
+388,692
+261% +$1.24M 0.06% 270
2024
Q3 		$497K Hold
148,917
– – 0.01% 349
2024
Q2 		$444K Buy
148,917
+11,044
+8% +$30.7K 0.01% 367
2024
Q1 		$476K Hold
137,873
– – 0.02% 326
2023
Q4 		$185K Hold
137,873
– – 0.01% 301
2023
Q3 		$301K Hold
137,873
– – 0.01% 304
2023
Q2 		$330K Buy
137,873
+48,685
+55% +$123K 0.01% 307
2023
Q1 		$165K Hold
89,188
– – 0.01% 321
2022
Q4 		$172K Hold
89,188
– – 0.01% 317
2022
Q3 		$137K Sell
89,188
-45,812
-34% -$150K 0.01% 337
2022
Q2 		$379K Buy
+135,000
New +$332K 0.02% 297

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

J. Goldman & Co's TRVI Position: Q1 2026 in Review

J. Goldman & Co reduced its Trevi Therapeutics (TRVI) stake by 47% in Q1 2026, selling an estimated $2.32M and leaving 236,959 shares worth $2.83M. The position accounts for 0.08% of the portfolio, ranked #266.

J. Goldman & Co first reported a position in TRVI in Q2 2022 and has held it in 16 quarters since. The position peaked at $7.25M in Q3 2025. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • J. Goldman & Co held 236,959 shares of Trevi Therapeutics worth $2.83M as of Q1 2026.
  • J. Goldman & Co sold 207,398 Trevi Therapeutics shares in Q1 2026, an estimated $2.32M.
  • Trevi Therapeutics made up 0.08% of J. Goldman & Co's portfolio in Q1 2026, its #266 holding.
  • J. Goldman & Co first reported a position in Trevi Therapeutics in Q2 2022 and has held it in 16 quarters since.
  • J. Goldman & Co's Trevi Therapeutics position peaked at $7.25M in Q3 2025.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.